Investors
News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 28, 2019
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to...
-
Dec 12, 2018- Two-Part Randomized, Double-Blinded Placebo Controlled Clinical Study in Healthy Subjects Followed by Cystic Fibrosis Patients Enrolls First Adult Human Volunteer
Aridis Pharmaceuticals (NASDAQ: ARDS) announced today that the first subject has been enrolled in a Phase 1/2a clinical study evaluating the investigational candidate AR-501 for treatment of...
-
Dec 4, 2018- CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that the Cystic Fibrosis Foundation (CF Foundation) has more than doubled its research agreement for the clinical development of AR-501 from
-
Nov 13, 2018- Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies, or mAbs, to...
-
Nov 7, 2018- Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies, or mAbs, to...